Unapproved Botox: What Nurses Need to Know After FDA Warning Letters and a CDC Med Spa Investigation

Two federal actions send the same message to every aesthetic nurse: where your botulinum toxin comes from matters as much as how you inject it.

The FDA Warned 18 Websites Selling Unapproved Botulinum Toxin

In November 2025, the FDA issued 18 warning letters to operators of websites illegally marketing unapproved and misbranded botulinum toxin products, often sold under the guise of popular injectables such as Botox (FDA; Dermatology Times).

The FDA warned that counterfeit or unapproved products from unauthorized sources may be adulterated, contaminated, improperly stored or ineffective, and can cause serious harm, including botulism-like symptoms.

FDA-approved botulinum toxin products, such as onabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin) and daxibotulinumtoxinA-lanm (Daxxify), are prescription-only and should be purchased through authorized distributors.

The CDC Investigated a Colorado Med Spa

On October 8, 2026, the CDC's Morbidity and Mortality Weekly Report described an investigation of a Colorado medical spa that administered a botulinum toxin product not approved by the FDA (CDC MMWR).

• A poison center report in January 2026 started the investigation.
• Public health officials surveyed 52 patients who received botulinum toxin at the med spa; 27 responded. In total, three women reported symptoms after receiving the same unapproved product from the same lot.
• Symptoms included blurred vision, voice changes, headache, trouble breathing, and arm and leg weakness. All three recovered.
• None of the patients knew the product was not FDA-approved.
• The provider reported buying the unapproved products from an online supplier.

Investigators also found practice problems that written policies are meant to prevent:

• Use of a preservative-containing diluent
• Single-dose vials used for multiple patients
• Inadequate temperature monitoring
• Reconstituted, unlabeled product stored and used past its beyond-use date

The provider received a public health order to stop using unapproved products immediately, and a formal complaint was submitted against the provider's license.

“Providers should not purchase or administer unapproved BoNT products from unauthorized sources.” — CDC, MMWR, October 8, 2026

What This Means for Your Practice

• Use only FDA-approved products purchased through authorized distributors. If a price looks too good to be true, verify before you order.
• Check the packaging, label and lot number against the manufacturer's U.S. product.
• Follow the prescribing information for reconstitution, single-dose use, storage and beyond-use dating.
• Keep temperature logs and lot records for every vial.
• Report suspected adverse events to FDA MedWatch, and call your poison center (1-800-222-1222) for suspected toxin effects.

Need written purchasing, storage and lot-tracking policies for your practice? Our sister site, Aesthetic Nursing Policy & Procedures, builds practice-specific policies and procedures manuals.

Educational information only, not legal advice. Requirements vary by state; confirm with your state board. Courses are provided by a California BRN Provider, #18009. BOTOX® is a registered trademark of Allergan, an AbbVie company.

Sources

• CDC, MMWR: Investigation of Unapproved Botulinum Toxin Product Administered at a Medical Spa, Colorado, 2025–2026, October 8, 2026
• FDA: FDA Warns Companies Over Illegal Marketing of Botox and Related Products, November 2025
• Dermatology Times: FDA Issues Warnings to Websites Illegally Marketing Botox and Related Products, November 5, 2025